VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Sage Therapeutics Executive Compensation (FY24)

SAGE · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Barry Greene
Median of the other named officers
$2,581,710
5 officers, excluding the chief executive
Latest say-on-pay support
=
April 16, 2025
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Sage Therapeutics brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 4, 2026Latest filing (8-K): June 13, 2025
10 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Sage Therapeutics brief$500Get the executive brief
Velarion Intel, one year, every company
445 figures on this page: 437 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Barry Greene: $6,237,491 → $7,112,589 (14.0% higher)
Say-on-pay support: 95.4% → 76.7% (18.7 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Sage Therapeutics' chief executive and what were they paid?
Barry Greene, Chief Executive Officer and President, received $7,112,589 in total compensation for fiscal 2024. Greene's total was 14.0% higher than the $6,237,491 reported for fiscal 2023.
What was Sage Therapeutics' say-on-pay result?
The say-on-pay proposal drew 76.7% of votes cast for or against in favor at the meeting held April 16, 2025 for fiscal 2024.
Which companies are in Sage Therapeutics' peer group?
The disclosed peer group includes ACADIA Pharmaceuticals Inc., Agios Pharmaceuticals, Inc., Alector, Inc., Amicus Therapeutics, Inc. and Amylyx Pharmaceuticals, among others. The 2024 Peer Group names ACADIA Pharmaceuticals Inc., Agios Pharmaceuticals, Inc., Alector, Inc., Amicus Therapeutics, Inc. and Amylyx Pharmaceuticals, among others. The 2025 Peer Group includes Ardelyx, BioCryst Pharmaceuticals, Dynavax Technologies, Esperion Therapeutics and Ironwood Pharmaceuticals, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Barry Greene
Chief Executive Officer and President
◇—◇◇◇—◇◇
Laura Gault
Former Chief Medical Officer
◇◇◇◇◇—◇◇
Christopher Benecchi
Chief Operating Officer and Treasurer
◇◇◇◇◇—◇◇
Anne Marie Cook
Former Senior Vice President, General Counsel and Secretary
◇◇◇◇◇—◇◇
Kimi Iguchi
Former Chief Financial Officer and Treasurer
◇◇◇◇◇—◇◇
Albert Robichaud
Former Chief Scientific Officer
◇◇◇◇◇—◇◇
Gregory Shiferman
Senior Vice President, General Counsel and Secretary
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Barry Greene
Chief Executive Officer and President
◇—◇◇◇—◇◇
Albert Robichaud
Former Chief Scientific Officer
Departed during or after this year
◇—◇◇——◇◇
Christopher Benecchi
Chief Operating Officer and Treasurer
◇—◇◇◇—◇◇
Anne Marie Cook
Former Senior Vice President, General Counsel and Secretary
◇—◇◇◇—◇◇
Kimi Iguchi
Former Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Gregory Shiferman
Senior Vice President, General Counsel and Secretary
◇—◇◇◇—◇◇
Laura Gault
Former Chief Medical Officer
◇◇◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Barry Greene
Chief Executive Officer and President
◇—◇◇◇—◇◇
Kimi Iguchi
Former Chief Financial Officer and Treasurer
Departed during or after this year
◇—◇◇——◇◇
Christopher Benecchi
Chief Operating Officer and Treasurer
◇◇◇◇◇—◇◇
Anne Marie Cook
Former Senior Vice President, General Counsel and Secretary
Departed during or after this year
◇—◇◇——◇◇
Laura Gault
Former Chief Medical Officer
Departed during or after this year
◇—◇◇◇—◇◇
Gregory Shiferman
Senior Vice President, General Counsel and Secretary
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Anne Marie CookOPTION◇——◇—◇—
Anne Marie CookOPTION◇——◇—◇—
Anne Marie CookOPTION◇——◇—◇◇
Anne Marie CookPSU◇—◇—◇—◇
Anne Marie CookOPTION◇——◇—◇◇
Anne Marie CookOPTION◇——◇—◇◇
Anne Marie CookPSU◇—◇—◇—◇
Anne Marie CookPSU◇—◇—◇—◇
Anne Marie CookOPTION◇——◇—◇◇
Anne Marie CookOPTION◇——◇—◇◇
Anne Marie CookOPTION◇——◇—◇◇
Anne Marie CookOPTION◇——◇—◇◇
Anne Marie CookOPTION◇——◇—◇◇
Anne Marie CookOPTION◇——◇—◇◇
Barry E. GreenePSU◇—◇—◇—◇
Barry E. GreenePSU◇—◇—◇—◇
Barry E. GreeneOPTION◇——◇—◇◇
Christopher BenecchiOPTION◇——◇—◇◇
Christopher BenecchiPSU◇—◇—◇—◇
Christopher BenecchiPSU◇—◇—◇—◇
Christopher BenecchiOPTION◇——◇—◇◇
Christopher BenecchiPSU◇—◇—◇—◇
Christopher BenecchiPSU◇—◇—◇—◇
Gregory ShifermanOPTION◇——◇—◇◇
Gregory ShifermanPSU◇—◇—◇—◇
Gregory ShifermanPSU◇—◇—◇—◇
Gregory ShifermanOPTION◇——◇—◇◇
Gregory ShifermanOPTION◇——◇—◇◇
Kimi IguchiPSU◇—◇—◇—◇
Laura GaultPSU◇—◇—◇—◇
Laura GaultOPTION◇——◇—◇◇
Laura GaultPSU◇—◇—◇—◇
Laura GaultPSU◇—◇—◇—◇
Senior VicePSU◇—◇—◇—◇
Senior ViceOPTION◇——◇—◇◇
Senior ViceOPTION◇——◇—◇◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Barry GreeneOption◇—◇1/4/2031
Option◇—◇2/13/2034
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/13/2033
PSU◇◇——
Option◇—◇2/11/2032
PSU◇◇——
Laura GaultPSU◇◇——
Option◇—◇11/1/2032
Option◇—◇2/13/2034
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/13/2033
Christopher BenecchiOption◇—◇2/13/2034
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇11/1/2034
Option◇—◇2/13/2033
PSU◇◇——
Option◇—◇10/1/2031
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇6/16/2032
Option◇—◇2/11/2032
Kimi IguchiOption◇—◇2/13/2034
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/13/2033
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/11/2032
Option◇—◇2/10/2031
Gregory ShifermanOption◇—◇11/1/2034
Option◇—◇2/21/2031
PSU◇◇——
Option◇—◇2/13/2034
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jeffrey M. Jonas
◇—◇——◇◇
Geno Germano
Board chair
◇—◇———◇
James M. Frates
◇—◇———◇
Michael F. Cola
◇—◇———◇
Elizabeth Barrett
◇—◇———◇
Jessica Federer
◇—◇———◇
George Golumbeski
◇—◇———◇
Steven Paul
◇—————◇
Kevin P. Starr
◇—————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • ACADIA Pharmaceuticals Inc. ACAD
  • Agios Pharmaceuticals, Inc. AGIO
  • Alector, Inc. ALEC
  • Amicus Therapeutics, Inc. FOLD
  • Amylyx Pharmaceuticals AMLX
  • Apellis Pharmaceuticals, Inc. APLS
  • Ardelyx ARDX
  • Axsome Therapeutics, Inc. AXSM
  • BioCryst Pharmaceuticals BCRX
  • Blueprint Medicines Corporation BPMC
  • Cerevel Therapeutics, Inc. CERE
  • CRISPR Therapeutics, Inc. CRSP
  • Deciphera Pharmaceuticals, Inc. DCPH
  • Dynavax Technologies DVAX
  • Esperion Therapeutics ESPR
  • Exelixis, Inc. EXEL
  • FibroGen, Inc. symbol not shown
  • Halozyme Therapeutics, Inc. HALO
  • Harmony Biosciences Holdings, Inc. HRMY
  • Insmed, Inc. INSM
  • Intra-Cellular Therapies, Inc. ITCI
  • Ironwood Pharmaceuticals IRWD
  • Mirati Therapeutics, Inc. MRTX
  • Performance PFGC
  • Rhythm Pharmaceuticals, Inc. RYTM
  • Supernus Pharmaceuticals, Inc. SUPN
  • Tarsus Pharmaceuticals TARS
  • Travere Therapeutics TVTX
  • Ultragenyx Pharmaceutical Inc. RARE
  • Weight symbol not shown
2024 Peer Group
  • ACADIA Pharmaceuticals Inc. ACAD
  • Agios Pharmaceuticals, Inc. AGIO
  • Alector, Inc. ALKT
  • Amicus Therapeutics, Inc. FOLD
  • Amylyx Pharmaceuticals AMLX
  • Apellis Pharmaceuticals, Inc. APLS
  • Axsome Therapeutics, Inc. AXSM
  • Blueprint Medicines Corporation symbol not shown
  • Cerevel Therapeutics, Inc. CERE
  • CRISPR Therapeutics, Inc. CRSP
  • Deciphera Pharmaceuticals, Inc. DCPH
  • Halozyme Therapeutics, Inc. HALO
  • Harmony Biosciences Holdings, Inc. symbol not shown
  • Insmed, Inc. INSM
  • Intra-Cellular Therapies, Inc. symbol not shown
  • Mirati Therapeutics, Inc. MRTX
  • Rhythm Pharmaceuticals, Inc. RYTM
  • Supernus Pharmaceuticals, Inc. SUPN
  • Ultragenyx Pharmaceutical Inc. symbol not shown
2025 Peer Group
  • Ardelyx ARDX
  • BioCryst Pharmaceuticals BCRX
  • Dynavax Technologies DVAX
  • Esperion Therapeutics ESPR
  • Ironwood Pharmaceuticals IRWD
  • Mirium Pharmaceuticals MIRM
  • Tarsus Pharmaceuticals TARS
  • Travere Therapeutics TVER

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024April 16, 2025=◇◇◇
2023April 16, 2024=◇◇◇
2022April 17, 2023=◇◇◇
2020June 10, 2021=◇◇◇
2019June 9, 2020=◇◇◇
2018June 5, 2019=◇◇◇
2017June 6, 2018=◇◇◇
2016June 7, 2017=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Barry Greene (Chief Executive Officer and President), FY2024 total compensation $7,112,589 (base salary $830,712) [exec_comp, SEC accession 0000950170-25-058060, filed 2025-04-24]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Sage Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Sage Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Sage Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Sage Therapeutics' disclosed peer group is defensible, who names Sage Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
445 figures on this page: 437 cited to the filing that reported them, 8 calculated from figures it prints.
437 cited to the filing
8 calculated from the filing

Documents cited

  1. 0001193125-25-140730
    Proposal 4: Amendment to the 2014 Employee Stock Purchase Plan” in the Company’s Definitive Proxy Statement for the 2025 Annual Meeting, filed with the U.S.
  2. 0000950170-25-058060
    EXECUTIVE OFFICER AND DIRECTOR COMPENSATION · Grants of Plan-Based Awards
  3. 0001193125-24-159130
    Abstain 52,272,319 1,106,440 26,195 3.
  4. 0001193125-24-110075
  5. 0001193125-23-168975
  6. 0001193125-21-187781
    Non-Votes 52,564,179 81,693 4,473 0 3.
  7. 0001193125-20-165675
    Proposal 1 at the Annual Meeting.
  8. 0001193125-19-167248
    Proposal 1 at the Annual Meeting.
  9. 0001193125-18-188137
    Proposal 1 at the Annual Meeting.
  10. 0001193125-17-198612
    Proposal 1 at the Annual Meeting.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Sage Therapeutics executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/SAGE (accessed 2026).
Short form: data: Velarion

The Sage Therapeutics brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Sage Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Sage Therapeutics discloses

The companies named in SAGE's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Agios Pharmaceuticals, Inc.Alector, Inc.Amicus Therapeutics, Inc.Amylyx PharmaceuticalsApellis Pharmaceuticals, Inc.ArdelyxAxsome Therapeutics, Inc.BioCryst PharmaceuticalsBlueprint Medicines CorporationCerevel Therapeutics, Inc.CRISPR Therapeutics, Inc.Deciphera Pharmaceuticals, Inc.Dynavax TechnologiesEsperion TherapeuticsExelixis, Inc.Halozyme Therapeutics, Inc.Harmony Biosciences Holdings, Inc.Insmed, Inc.Intra-Cellular Therapies, Inc.Ironwood PharmaceuticalsMirati Therapeutics, Inc.PerformanceRhythm Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy